Analysis of Conformational Determinants Underlying HSP90-Kinase Interaction

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Kancha, Rama Krishna ^a   Bartosch, Natalie ^b   Duyster, Justus ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALVESPIMYCIN; BCR ABL PROTEIN; CD135 ANTIGEN; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; IMATINIB; LAPATINIB; MIDOSTAURIN; NVP TAE 684; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TANESPIMYCIN; UNCLASSIFIED DRUG; WZ 4002;

ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY;

ANIMALS; BENZOQUINONES; BLOTTING, WESTERN; CELL LINE; CELL LINE, TUMOR; FUSION PROTEINS, BCR-ABL; HSP90 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOPRECIPITATION; K562 CELLS; LACTAMS, MACROCYCLIC; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; RECEPTOR, ERBB-2;

EID: 84879765079     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0068394     Document Type: Article

References (28)

1. Whitesell L, Lindquist SL, (2005) HSP90 and the chaperoning of cancer. Nature reviews 5: 761-772.
2. Pale M, Jarosz DF, Lindquist S, (2010) HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nature reviews 11: 515-528.
3. Grbovic OM, Basso AD, Sawai A, Ye Q, Friedlander P, et al. (2006) V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. Proceedings of the National Academy of Sciences of the United States of America 103: 57-62.
4. Giannini A, Bijlmakers MJ, (2004) Regulation of the Src family kinase Lck by Hsp90 and ubiquitination. Molecular and cellular biology 24: 5667-5676.
5. Falsone SF, Leptihn S, Osterauer A, Haslbeck M, Buchner J, (2004) Oncogenic mutations reduce the stability of SRC kinase. Journal of molecular biology 344: 281-291.
6. da Rocha Dias S, Friedlos F, Light Y, Springer C, Workman P, et al. (2005) Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin. Cancer research 65: 10686-10691.
7. Xu W, Mimnaugh E, Rosser MF, Nicchitta C, Marcu M, et al. (2001) Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90. The Journal of biological chemistry 276: 3702-3708.
8. Xu W, Yuan X, Xiang Z, Mimnaugh E, Marcu M, et al. (2005) Surface charge and hydrophobicity determine ErbB2 binding to the Hsp90 chaperone complex. Nature structural & molecular biology 12: 120-126.
9. Kancha RK, von Bubnoff N, Bartosch N, Peschel C, Engh RA, et al. (2011) Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib. PloS one 6: e26760.
10. Kancha RK, von Bubnoff N, Miething C, Peschel C, Gotze KS, et al. (2008) Imatinib and leptomycin B are effective in overcoming imatinib-resistance due to Bcr-Abl amplification and clonal evolution but not due to Bcr-Abl kinase domain mutation. Haematologica 93: 1718-1722.
11. Kancha RK, Grundler R, Peschel C, Duyster J, (2007) Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations. Experimental hematology 35: 1522-1526.
12. Coutinho S, Jahn T, Lewitzky M, Feller S, Hutzler P, et al. (2000) Characterization of Ggrb4, an adapter protein interacting with Bcr-Abl. Blood 96: 618-624.
13. Hubinger G, Scheffrahn I, Muller E, Bai R, Duyster J, et al. (1999) The tyrosine kinase NPM-ALK, associated with anaplastic large cell lymphoma, binds the intracellular domain of the surface receptor CD30 but is not activated by CD30 stimulation. Experimental hematology 27: 1796-1805.
14. An WG, Schulte TW, Neckers LM, (2000) The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome. Cell growth & differentiation 11: 355-360.
15. Aertgeerts K, Skene R, Yano J, Sang BC, Zou H, et al. (2011) Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein. The Journal of biological chemistry 286: 18756-18765.
16. Zhou W, Ercan D, Chen L, Yun CH, Li D, et al. (2009) Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 462: 1070-1074.
17. Schaefer G, Shao L, Totpal K, Akita RW, (2007) Erlotinib directly inhibits HER2 kinase activation and downstream signaling events in intact cells lacking epidermal growth factor receptor expression. Cancer research 67: 1228-1238.
18. Wang SE, Narasanna A, Perez-Torres M, Xiang B, Wu FY, et al. (2006) HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer cell 10: 25-38.
19. Engelman JA, Zejnullahu K, Gale CM, Lifshits E, Gonzales AJ, et al. (2007) PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer research 67: 11924-11932.
20. Guix M, Granja Nde M, Meszoely I, Adkins TB, Wieman BM, et al. (2008) Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers. Journal of clinical oncology 26: 897-906.
21. Vajpai N, Strauss A, Fendrich G, Cowan-Jacob SW, Manley PW, et al. (2008) Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib. The Journal of biological chemistry 283: 18292-18302.
22. Taipale M, Krykbaeva I, Koeva M, Kayatekin C, Westover KD, et al. (2012) Quantitative analysis of hsp90-client interactions reveals principles of substrate recognition. Cell 150: 987-1001.
23. Huang SS, Koh HA, Konish Y, Bullock LD, Huang JS, (1990) Differential processing and turnover of the oncogenically activated neu/erb B2 gene product and its normal cellular counterpart. The Journal of biological chemistry 265: 3340-3346.
24. Salas A, Ponnusamy S, Senkal CE, Meyers-Needham M, Selvam SP, et al. (2011) Sphingosine kinase-1 and sphingosine 1-phosphate receptor 2 mediate Bcr-Abl1 stability and drug resistance by modulation of protein phosphatase 2A. Blood 117: 5941-5952.
25. Hubinger G, Wehnes E, Xue L, Morris SW, Maurer U, (2003) Hammerhead ribozyme-mediated cleavage of the fusion transcript NPM-ALK associated with anaplastic large-cell lymphoma. Experimental hematology 31: 226-233.
26. Weisberg E, Ray A, Nelson E, Adamia S, Barrett R, et al. (2011) Reversible resistance induced by FLT3 inhibition: a novel resistance mechanism in mutant FLT3-expressing cells. PloS one 6: e25351.
27. Bonvini P, Gastaldi T, Falini B, Rosolen A, (2002) Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin. Cancer research 62: 1559-1566.
28. Yao Q, Nishiuchi R, Li Q, Kumar AR, Hudson WA, et al. (2003) FLT3 expressing leukemias are selectively sensitive to inhibitors of the molecular chaperone heat shock protein 90 through destabilization of signal transduction-associated kinases. Clinical cancer research 9: 4483-4493.